Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
暂无分享,去创建一个
J. Warner | T. Choueiri | M. Galsky | B. Halmos | S. Peters | G. Lyman | B. Rini | G. Schwartz | Y. Shyr | L. Fecher | L. Schapira | Christopher A. Lemmon | C. Friese | P. Grivas | N. Pennell | O. Panagiotou | D. Rivera | S. Goel | Huili Zhu | T. Halfdanarson | N. Kuderer | M. Thompson | D. Doroshow | S. Rubinstein | S. Revankar | C. Painter | Shilpa Gupta | D. Farmakiotis | Albert C. Yeh | A. Olszewski | Z. Bakouny | A. Schmidt | Zhuoer Xie | D. Shah | M. Puc | A. Khaki | G. de Lima Lopes | J. Hawley | P. Egan | Chih-Yuan Hsu | S. Mishra | J. Wu | Sumit A Shah | Jonathan T Arcobello | A. Yeh | Brendan Lee
[1] S. Lofgren,et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2020, Annals of Internal Medicine.
[2] Lee-Jen Wei,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.
[3] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[4] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.
[5] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[6] V. Torri,et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.
[7] R. Bhattacharyya,et al. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.
[8] Amit N. Patel,et al. Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. , 2020, The New England journal of medicine.
[9] Amit N. Patel,et al. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.
[10] Jun Yu Li,et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[11] Zhiquan Hu,et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[12] Alokkumar Jha,et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.
[13] D. Kerr,et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.
[14] E. Price-Haywood,et al. Hospitalization and Mortality among Black Patients and White Patients with Covid-19 , 2020, The New England journal of medicine.
[15] R. Bruno,et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[16] Amit N. Patel,et al. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.
[17] J. Sterne,et al. Collider bias undermines our understanding of COVID-19 disease risk and severity , 2020, Nature Communications.
[18] R. Cumming,et al. Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards , 2020, Journal of Epidemiology & Community Health.
[19] Adolph Reed,et al. Racial Health Disparities and Covid-19 - Caution and Context. , 2020, The New England journal of medicine.
[20] S. Kalnicki,et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.
[21] Amit N. Patel,et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.
[22] J. Warner,et al. The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer , 2020, Cancer Cell.
[23] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[24] Jeremy Warner,et al. Crowdsourcing a crisis response for COVID-19 in oncology , 2020, Nature Cancer.
[25] C. Yancy,et al. COVID-19 and African Americans. , 2020, JAMA.
[26] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[27] C. Wang,et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.
[28] M. Chua,et al. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China , 2020, JAMA oncology.
[29] D. Raoult,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.
[30] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[32] Louise Bowman,et al. The Magic of Randomization versus the Myth of Real-World Evidence. , 2020, The New England journal of medicine.
[33] J. Baillie,et al. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.
[34] R. Baric,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.
[35] E. Paskett,et al. Overcoming Barriers to Clinical Trial Enrollment. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[36] N. Curtis,et al. The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms , 2018, Front. Immunol..
[37] Hanspeter Pfister,et al. UpSet: Visualization of Intersecting Sets , 2014, IEEE Transactions on Visualization and Computer Graphics.
[38] Søren Højsgaard,et al. A Kenward-Roger approximation and parametric bootstrap methods for tests in linear mixed models: The R Package pbkrtest , 2014 .
[39] Kosuke Imai,et al. mediation: R Package for Causal Mediation Analysis , 2014 .
[40] Julie Dyall,et al. Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.
[41] Gary King,et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .
[42] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[43] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[44] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[45] B. Stricker,et al. Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.
[46] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[47] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .